Pre-clinical evaluation of second generation PIM inhibitors for the treatment of T-cell acute lymphoblastic leukemia and lymphoma.

MLA

De Smedt, Renate, et al. “Pre-Clinical Evaluation of Second Generation PIM Inhibitors for the Treatment of T-Cell Acute Lymphoblastic Leukemia and Lymphoma.” Haematologica, vol. 104, no. 1, Jan. 2019, pp. e17–20. EBSCOhost, https://doi.org/10.3324/haematol.2018.199257.

APA

De Smedt, R., Peirs, S., Morscio, J., Matthijssens, F., Roels, J., Reunes, L., Lintermans, B., Goossens, S., Lammens, T., Van Roy, N., Touzart, A., Jenni, S., Tsai, Y.-C., Lovisa, F., Mussolin, L., Serafin, V., Van Nieuwerburgh, F., Deforce, D., Uyttebroeck, A., … Van Vlierberghe, P. (2019). Pre-clinical evaluation of second generation PIM inhibitors for the treatment of T-cell acute lymphoblastic leukemia and lymphoma. Haematologica, 104(1), e17–e20. https://doi.org/10.3324/haematol.2018.199257

Chicago

De Smedt, Renate, Sofie Peirs, Julie Morscio, Filip Matthijssens, Juliette Roels, Lindy Reunes, Beatrice Lintermans, et al. 2019. “Pre-Clinical Evaluation of Second Generation PIM Inhibitors for the Treatment of T-Cell Acute Lymphoblastic Leukemia and Lymphoma.” Haematologica 104 (1): e17–20. doi:10.3324/haematol.2018.199257.